Innovative Technology Otolith Labs utilizes a patented non-invasive Vestibular Resonance Therapy (nVRT) technology that addresses chronic vertigo, offering a novel solution in the medical device market for vestibular disorders.

Strong Funding & Growth With a successful $20 million Series A funding round led by Morningside Ventures and a revenue range of 10 to 25 million dollars, the company demonstrates robust financial backing and significant market traction.

Regulatory Progress The company's FDA Breakthrough Device Designation indicates advancing regulatory approval efforts, making it a promising partner for healthcare providers seeking state-of-the-art vertigo treatments.

Market Opportunity Addressing a condition experienced by over 11 million Americans, Otolith Labs offers a targeted device for a large unmet medical need, presenting significant sales potential in both domestic and international markets.

Strategic Leadership The appointment of a Chief Clinical Officer and ongoing clinical research underscore their focus on clinical validation, which can facilitate partnerships with healthcare providers and distribution networks.